share_log

BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate

BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate

BiondVax 吹捧来自吸入的 COVID-19 候选治疗药物的更多临床前数据
Benzinga Real-time News ·  2023/01/23 11:52
  • BiondVax Pharmaceuticals Ltd (NYSE:BVXV) announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug.
  • The study compared weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg dose of the NanoAb three hours before infection experienced no significant weight loss over the six-day trial.
  • But the untreated control group's weight declined 12% on average, a highly statistically significant difference.
  • The prophylactic results follow previously reported data from the same study indicating that compared to the control (placebo) group, hamsters treated with a 2mg dose of BiondVax's inhaled NanoAb one day after infection had negligible SARS-CoV-2 viral titers in their lungs, and experienced a milder and shorter illness in comparison to the placebo group that had at least 30-times higher viral titers.
  • This preclinical trial continues with additional arms testing lower therapeutic doses (0.66mg and 0.22mg). In 2023, BiondVax is expected to conduct a preclinical toxicity study.
  • The company also expects to scale up its manufacturing processes for NanoAbs for the first-in-human Phase 1/2a trial, which is planned for Q4 2023.
  • Price Action: BVXV shares are up 2.55% at $2.82 on the last check Monday.
  • BiondVax 制药有限公司 纽约证券交易所代码：BVXV）公布了其创新吸入式NanoAB COVID-19 药物的临床前概念验证研究的更多结果。
  • 该研究比较了两组仓鼠的减肥情况。在为期六天的试验中，仓鼠在感染前三小时服用了中等剂量的0.66mg的NanoAB，体重没有明显减轻。
  • 但是未经治疗的对照组的体重平均下降了12％，这是一个非常显著的统计学差异。
  • 预防性结果遵循先前报道的同一项研究的数据，该数据表明，与对照（安慰剂）组相比，感染后一天接受2mg剂量的BiondVax吸入nanoAb治疗的仓鼠肺部的SARS-CoV-2病毒滴度可以忽略不计，与病毒滴度至少高出30倍的安慰剂组相比，患病时间更轻、更短。
  • 这项临床前试验仍在继续，将对较低的治疗剂量（0.66mg 和 0.22mg）进行额外的ARM测试。预计在2023年，BiondVax将进行一项临床前毒性研究。
  • 该公司还预计将扩大NanoABS的制造工艺，用于首次人体1/2a期试验，该试验计划于2023年第四季度进行。
  • 价格走势： 周一的最后一张支票中，BVXV股价上涨2.55％，至2.82美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发